Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients

Coronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies combination against COVID-19. Standard antiviral thera...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Hegazy Sahar K., Tharwat Samar, Hassan Ahmed H.
Natura:	Articolo
Lingua:	English
Pubblicazione:	De Gruyter 2023-08-01
Serie:	Open Medicine
Soggetti:	antivirals casirivimab and imdevimab covid-19 favipiravir remdesivir
Accesso online:	https://doi.org/10.1515/med-2023-0768

Documenti analoghi

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
di: Sahar K. Hegazy, et al.
Pubblicazione: (2023-06-01)

The effect of casirivimab with imdevimab on disease progression in nonsevere COVID‐19 patients in a single hospital in Japan
di: Junpei Komagamine, et al.
Pubblicazione: (2022-05-01)

An initial experience with antibody cocktail CASIRIVIMAB and IMDEVIMAB in a center of excellence: A retrospective case series of 3 patients and literature review
di: P Amal Johnson, et al.
Pubblicazione: (2021-01-01)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
di: Netana H. Markovitz, MD, et al.
Pubblicazione: (2022-09-01)

Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial
di: Imam Adi Wicaksono, et al.
Pubblicazione: (2023-12-01)

Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
di: Reka Gabriela, et al.
Pubblicazione: (2021-09-01)

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study
di: Marina S. Lebedkina, et al.
Pubblicazione: (2023-08-01)

Successful use of tocilizumab and casirivimab/imdevimab in a twin pregnancy with critical COVID-19 – A case report
di: Nina Grasselli Kmet, et al.
Pubblicazione: (2024-06-01)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
di: Flonza Isa, et al.
Pubblicazione: (2022-09-01)

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
di: Martin Heller, et al.
Pubblicazione: (2023-04-01)

Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia
di: Alessandro Cozzi-Lepri, et al.
Pubblicazione: (2024-03-01)

The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India
di: Aneesh Puthiyedath Joy, et al.
Pubblicazione: (2022-03-01)

Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection
di: Kentaro Nagaoka, et al.
Pubblicazione: (2022-06-01)

Retraction of “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
di: Hegazy Sahar K., et al.
Pubblicazione: (2023-11-01)

Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
di: Ashli M. Heustess, et al.
Pubblicazione: (2021-05-01)

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
di: Andrea T. Hooper, et al.
Pubblicazione: (2022-12-01)

Antibody Cocktail in Moderate to Severe COVID-19 Infection: A Series of 10 Cases
di: Rohit Hanmanta Bhandari, et al.
Pubblicazione: (2022-06-01)

Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST)
di: Taweegrit Siripongboonsitti, et al.
Pubblicazione: (2024-07-01)

Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta
di: Hadiatussalamah Hadiatussalamah, et al.
Pubblicazione: (2023-09-01)

Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers—An MD Study
di: Mauro Bringas, et al.
Pubblicazione: (2022-09-01)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
di: Valentina Mazzotta, et al.
Pubblicazione: (2022-04-01)

Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab
di: Laura Ballotta, et al.
Pubblicazione: (2022-09-01)

Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review
di: Pradeep Balasubramanian, et al.
Pubblicazione: (2022-01-01)

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
di: Gaetano Cicchitto, et al.
Pubblicazione: (2022-03-01)

Adjusted green spectrophotometric determination of favipiravir and remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models
di: Mohamed S. Imam, et al.
Pubblicazione: (2023-07-01)

Perbandingan Angka Kematian Terapi Antiviral Favipiravir dan Remdesivir pada Pasien COVID-19 Di RSUP Dr. Sardjito Yogyakarta
di: Nova Satriyani, et al.
Pubblicazione: (2023-01-01)

Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study
di: Chavalertsakul K, et al.
Pubblicazione: (2024-05-01)

Efficacy of Antibody Cocktail Drug in COVID-19 Positive Patients: A Retrospective Single-centered Study
di: Manoranjan Dash, et al.
Pubblicazione: (2023-02-01)

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
di: Megan Neary, et al.
Pubblicazione: (2024-11-01)

Comparison of Monoclonal Antibody Cocktail (Casirivimab-Imdevimab) Treatment With Remdesivir and Favipiravir in Mild to Moderate COVID-19 Infection: A Retrospective Study
di: Rahul Rajaram Tambe, et al.
Pubblicazione: (2023-02-01)

Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis
di: Robert Hoepner, et al.
Pubblicazione: (2022-03-01)

FAVIPIRAVIR AND DEXAMETHASONE IN MANAGEMENT OF SARS-COV2 INFECTION
di: M. Latief, et al.
Pubblicazione: (2021-05-01)

Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry
di: Yahdiana Harahap, et al.
Pubblicazione: (2023-05-01)

Successful treatment of persistent and severe SARS‐CoV‐2 infection in a high‐risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies
di: Fernanda Braga Seganfredo, et al.
Pubblicazione: (2022-11-01)

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation
di: Afnan S. Batubara, et al.
Pubblicazione: (2023-06-01)

First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in Romania
di: Iustina Violeta Stan, et al.
Pubblicazione: (2022-01-01)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
di: Thomas J. Woltemate, et al.
Pubblicazione: (2021-10-01)

Evaluation of the effect of favipiravir on patients with COVID-19
di: Alireza Kamali, et al.
Pubblicazione: (2023-02-01)

Favipiravir: the hidden threat of mutagenic action
di: O. P. Zhirnov, et al.
Pubblicazione: (2021-05-01)

Neutralizing Antibody Therapeutics for COVID-19
di: Aeron C. Hurt, et al.
Pubblicazione: (2021-04-01)